A phase I study recently published in the Journal of Nuclear Medicine concluded that PRRT with Y-90 is safe in children and young adults. According to investigators, PRRT with Y-90 demonstrated a favorable safety profile in children and young adults with refractory solid tumors that express somatostatin receptors. No dose-limited toxicities were observed. However, the maximum tolerable dose of this therapy varies from patient to patient.
Overall, subjects reported improved quality of life during PRRT with Y-90. Click here to access the abstract of the article entitled Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors.